Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

In this Phase III study (n=514), the addition of atezolizumab to vemurafenib and cobimetinib was associated with prolonged progression-free survival (15.1 vs 10.6 months with vemurafenib plus cobimetinib [control]; HR 0.78; 95% CI 0.63-0.97; p=0.025).


The Lancet